IMVT 28.97 Immunovant, Inc.
| Range: | 24.67-45.58 | Vol Avg: | 944387 | Last Div: | 0 | Changes: | 0.47 |
| Beta: | 0.71 | Cap: | 4.45B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 21 2019 | Empoloyees: | 207 | ||
| CUSIP: | 45258J102 | CIK: | 0001764013 | ISIN: | US45258J1025 | Country: | US |
| CEO: | Dr. Peter Salzmann M.B.A., M.D. | Website: | https://immunovant.com | ||||
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Stock Details
IMVT 51
H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)
Douglas Tsao·Tue Sep 10 2024
H.C. Wainwright
IMVT 46
Immunovant price target lowered to $46 from $50 at Oppenheimer
Leland Gershell·Mon Jun 03 2024
Oppenheimer
IMVT 48
Immunovant (IMVT) PT Lowered to $48 at Guggenheim
Yatin Suneja·Thu May 30 2024
Guggenheim
IMVT 57
Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
Yasmeen Rahimi·Thu May 30 2024
Piper Sandler
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow